Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical : Reached Agreement with Japanese Government regarding Investigational Antibody Cocktail (casirivimab and imdevimab) for COVID-19

05/10/2021 | 02:04am EDT

May 10, 2021

Name of listed company: Chugai Pharmaceutical Co., Ltd.

Code number:

4519 (1st Section of Tokyo Stock Exchange)

Head office:

1-1,Nihonbashi-Muromachi2-Chome,Chuo-ku, Tokyo

President & CEO:

Osamu Okuda

Inquiries to:

Toshiya Sasai

Head of Corporate Communications Dept.

Tel: +81-(0)3-3273-0554

Chugai Reached Agreement with Japanese Government regarding Investigational Antibody Cocktail (casirivimab and imdevimab) for COVID-19

Chugai Pharmaceutical Co., Ltd. (the Company) announced that the Company has agreed with the Japanese government regarding the antibody cocktail casirivimab and imdevimab (hereafter, the antibody cocktail), which is being investigated as a potential treatment for COVID-19. Under this agreement, the Japanese government will secure the antibody cocktail for the year 2021 for domestic supply if it is approved by the regulatory authority in Japan.

The antibody cocktail combining two virus-neutralizing antibodies, casirivimab and imdevimab, was developed by U.S.-based Regeneron for the potential treatment and prevention of COVID-19. In August 2020, Roche and Regeneron announced a collaboration to develop, manufacture and distribute the antibody cocktail. In December of the same year, Chugai obtained development rights and exclusive commercialization rights in Japan for the antibody cocktail from Roche.

The COVID-19 pandemic, including the spread of infections of variants, has been persistent, and new treatment options continue to be pursued. The two potent virus-neutralizing antibodies administered together, bind non- competitively to the critical receptor binding domain of the virus spike protein, which may neutralize the activity against SARS-CoV-2 and protects against spike variants currently circulating in the human population*. Several overseas clinical trials have been conducted for the treatment and prevention of COVID-

19. In Japan, a Phase I clinical trial has been initiated in March of this year to examine the safety, tolerability, and pharmacokinetics in Japanese.

*Alina Baum, Benjamin O Fulton, Elzbieta Wloga, et al. Science 2020 Aug 21;369(6506):1014-101

We will continue to collaborate with the Japanese government to ensure appropriate and timely supply of the antibody cocktail upon regulatory approval.

This matter is not included in the earnings forecast for the fiscal year 2021 announced on February 4, 2021. No changes are expected to Chugai's financial prospects at this time, but we will promptly disclose any events that should be disclosed in the future.

###

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 10 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 May 2021 06:03:08 UTC.


© Publicnow 2021
All news about CHUGAI PHARMACEUTICAL CO., LTD.
04:42aTOSHIBA  : board chair likely to scrape through with reappointment at crucial AG..
RE
04:05aCHUGAI PHARMACEUTICAL  : Obtains Regulatory Approval for FoundationOne CDx Cance..
PU
06/21TOSHIBA  : releases internal report ahead of shareholder vote
RE
06/21TOSHIBA  : releases internal report ahead of shareholder vote
RE
06/18TOSHIBA  : Former U.S. Ambassador throws support behind embattled Toshiba board ..
RE
06/18Former u.s. ambassador to japan john roos issues statement on toshiba corp bo..
RE
06/18Ahead of pivotal AGM, Toshiba board chairman vows to be 'agent of positive ch..
RE
06/17Toshiba's top shareholder calls board 'ineffective' - statement
RE
06/17Toshiba's top shareholder calls board 'ineffective' - statement
RE
06/16TOSHIBA  : chairman says he may leave once problems fixed - WSJ
RE
More news
Financials
Sales 2021 829 B 7 490 M 7 490 M
Net income 2021 244 B 2 207 M 2 207 M
Net cash 2021 451 B 4 077 M 4 077 M
P/E ratio 2021 29,5x
Yield 2021 1,40%
Capitalization 7 184 B 64 846 M 64 916 M
EV / Sales 2021 8,12x
EV / Sales 2022 8,02x
Nbr of Employees 7 555
Free-Float 37,7%
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Last Close Price 4 370,00 JPY
Average target price 4 777,69 JPY
Spread / Average Target 9,33%
EPS Revisions
Managers and Directors
NameTitle
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO., LTD.-22.77%61 483
JOHNSON & JOHNSON4.10%431 456
ROCHE HOLDING AG12.99%328 650
PFIZER, INC.7.09%220 661
NOVARTIS AG3.00%210 615
ABBVIE INC.7.07%202 639